Article info
Neuromuscular
Original research
Eculizumab versus rituximab in generalised myasthenia gravis
- Correspondence to Dr Tobias Ruck, Department of Neurology, Heinrich Heine University Düsseldorf, Dusseldorf, Germany; Tobias.Ruck{at}med.uni-duesseldorf.de
Citation
Eculizumab versus rituximab in generalised myasthenia gravis
Publication history
- Received December 16, 2021
- Accepted February 22, 2022
- First published March 4, 2022.
Online issue publication
April 12, 2022
Article Versions
- Previous version (4 March 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.